Novartis and MorphoSys AG have formed a comprehensive, 10-year, $600 million strategic alliance for the discovery and development of biopharmaceuticals. The deal is aimed at establishing a pipeline of innovative drugs, and establishes Novartis as MorphoSys’s preferred collaborator for HuCAL-based drug discovery. According to a MorphoSys statement, this will allow the company to focus on drug discovery and development and help it wean itself from new or extended fee-for-service discovery de...